Mattes J A, Gittelman R
Arch Gen Psychiatry. 1983 Mar;40(3):317-21. doi: 10.1001/archpsyc.1983.01790030087011.
The growth in height and weight of 86 hyperactive children receiving methylphenidate hydrochloride (average, 40 mg/day for up to four years) was compared with general population norms on recently updated growth charts. A significant decrease in height percentile was apparent after 2, 3, and 4 years of treatment but not after one year. A significant loss in weight percentile occurred onward from the first year of treatment. Dosage was significantly associated with the decrease in height and weight percentile. Greater initial height and weight were associated with greater growth decrements. The use of adjunctive thioridazine hydrochloride (mean, 87 mg/day) did not influence the growth of children receiving methylphenidate. Although the magnitude of the growth suppressant effect in groups was small (dosage accounted for only 2% of the variance in final height), the results suggest that clinicians should monitor the growth of hyperactive children receiving stimulants and consider dosage reduction in individual cases should evidence of growth suppression occur.
将86名接受盐酸哌甲酯治疗（平均每日40毫克，最长四年）的多动儿童的身高和体重增长情况，与最新生长图表上的一般人群标准进行了比较。治疗2年、3年和4年后，身高百分位数明显下降，但1年后未出现这种情况。从治疗第一年起，体重百分位数就出现了显著下降。剂量与身高和体重百分位数的下降显著相关。初始身高和体重越高，生长减少幅度越大。使用辅助药物盐酸硫利达嗪（平均每日87毫克）对接受哌甲酯治疗的儿童的生长没有影响。尽管各组生长抑制作用的幅度较小（剂量仅占最终身高方差的2%），但结果表明，临床医生应监测接受兴奋剂治疗的多动儿童的生长情况，如出现生长抑制迹象，应考虑在个别病例中减少剂量。
